文献速递淋巴瘤白血病造血干细胞移植与细胞治疗

慢性淋巴细胞白血病中T细胞功能障碍由Siglec-10配体CD24和CD52介导

T-cell dysfunction in CLL is mediated through expression of Siglec-10 ligands CD24 and CD52 on CLL cells.
PubMed 文献 · Blood Adv · 2024-01-01

本研究探讨慢性淋巴细胞白血病(CLL)细胞抑制CAR T细胞活化与功能的机制,发现CD40激活的CLL细胞通过下调Siglec-10配体CD24和CD52导致T细胞功能障碍,阻断CD24和/或CD52可显著减轻CAR T细胞功能障碍,提示靶向CD24和CD52介导的CLL-T细胞相互作用可能是增强CLL中T细胞功能的有前景的治疗策略。

要点

  • CLL细胞存在时再刺激CAR T细胞导致细胞因子产生受损和增殖减少。
  • CD40激活的CLL细胞与T细胞直接接触不引起T细胞功能障碍。
  • 阻断CD24和/或CD52可显著减轻与静息CLL细胞共培养时的CAR T细胞功能障碍。

核心结论

  • CLL患者来源的T细胞可通过调控CLL-T细胞相互作用被重新激活,靶向CD24和CD52介导的CLL-T细胞相互作用可能是增强CLL中T细胞功能的有前景的治疗策略。

研究设计与样本

  • 本研究为体外实验研究,探讨CLL细胞抑制CAR T细胞活化与功能的机制。

主要发现

  • CLL来源的T细胞以延迟方式被激活,且在CLL细胞存在下再刺激CAR T细胞导致细胞因子产生受损和增殖减少。
  • 与CD40激活的CLL细胞共培养不导致T细胞功能障碍,且需要CD40刺激的CLL细胞与T细胞之间的直接细胞接触。
  • SRC激酶抑制剂达沙替尼阻止T细胞功能的挽救,独立于CD40介导的CLL细胞上共刺激和黏附配体水平增加。
  • CD40刺激的CLL细胞转录组分析显示CD40介导Siglec-10配体CD24和CD52下调,达沙替尼可阻止该下调。
  • 阻断CD24和/或CD52显著减轻与静息CLL细胞共培养时的CAR T细胞功能障碍。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Autologous T-cell-based therapies, such as chimeric antigen receptor (CAR) T-cell therapy, exhibit low success rates in chronic lymphocytic leukemia (CLL) and correlate with a dysfunctional T-cell phenotype observed in patients. Despite various proposed mechanisms of T-cell dysfunction in CLL, the specific CLL-derived factors responsible remain unidentified. This study aimed to investigate the mechanisms through which CLL cells suppress CAR T-cell activation and function. We found that CLL-derived T cells get activated, albeit in a delayed fashion, and specifically that restimulation of CAR T cells in the presence of CLL cells causes impaired cytokine production and reduced proliferation. Notably, coculture of T cells with CD40-activated CLL cells did not lead to T-cell dysfunction, and this required direct cell contact between the CD40-stimulated CLL cells and T cells. Inhibition of kinases involved in the CD40 signaling cascade revealed that the Spare Respiratory Capacity (SRC) kinase inhibitor dasatinib prevented rescue of T-cell function independent of CD40-mediated increased levels of costimulatory and adhesion ligands on CLL cells. Transcriptome profiling of CD40-stimulated CLL cells with or without dasatinib identified widespread differential gene expression. Selecting for surface receptor genes revealed CD40-mediated downregulation of the Sialic acid-binding Ig-like lectin 10 (Siglec-10) ligands CD24 and CD52, which was prevented by dasatinib, suggesting a role for these ligands in functional T-cell suppression in CLL. Indeed, blocking CD24 and/or CD52 markedly reduced CAR T-cell dysfunction upon coculture with resting CLL cells. These results demonstrated that T cells derived from CLL patients can be reinvigorated by manipulating CLL-T-cell interactions. Targeting CD24- and CD52-mediated CLL-T-cell interaction could be a promising therapeutic strategy to enhance T-cell function in CLL.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. van Bruggen JAC, Peters FS, Mes M, et al. T-cell dysfunction in CLL is mediated through expression of Siglec-10 ligands CD24 and CD52 on CLL cells. Blood Adv. 2024. PMID: 39042920. doi:10.1182/bloodadvances.2023011934

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。